CANF R&D to Revenue
Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares · R&D to Revenue
CANF R&D to Revenue
Latest reported1652.59%period ending
CANF FY R&D/Revenue (377.95% → 1652.59%)
Latest values, visible window
High-resolution chart · PNG
CANF r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 1,652.5949% | |
| 854.1543% | |
| 805.249% | |
| 958.3951% | |
| 1,154.7479% | |
| 1,566.3172% | |
| 540.1575% | |
| 159.0314% | |
| 624.0464% | |
| 3,585.8962% | |
| 2,340.9047% | |
| 0% | |
| 0% | |
| 0% | |
| 726.555% | |
| 377.9504% |